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INTRODUCTION
Salmonella Typhi (S. Typhi) has affected
mankind for the last 50,000 years (Kidgell
et al., 2002; Roumagnac et al., 2006), how-
ever the precise pathogenesis in humans
has largely remained a mystery (Crump
and Mintz, 2010). Typhoid fever, the sys-
temic disease caused by S. Typhi infec-
tion, is responsible for an estimated 21
million new infections annually resulting
in approximately 200,000–600,000 deaths
world-wide (Crump et al., 2004; Buckle
et al., 2012). If untreated, typhoid fever
may result in severe illness including the
complications of gastrointestinal bleed-
ing, bowel perforation, and sometimes
death. Transmission of S. Typhi occurs via
ingestion of faecally-contaminated food or
water (De Jong et al., 2012). Infection
risk has been associated with household
factors including contact with a recently
infected relative, poor sanitation and
hygiene infrastructure, which include spa-
tial associations with contaminated public
water sources (Vollaard et al., 2004; Sur
et al., 2009; Baker et al., 2011).
Much of what we know about human
Salmonella infection has been determined
from historical human vaccine and, sub-
sequently, challenge studies dating back
to 1896 (Waddington et al., 2014a).
Between 1952 and 1974, human chal-
lenge studies performed at the University
of Maryland served as a unique tool by
which to study host-pathogen interactions
including mechanistic hypotheses regard-
ing routes of infection, development of
clinical symptomatology and evolution of
host immune responses.
Initial improvements in sanitation
infrastructure occurring during the last
century in “western settings” and subse-
quently in the rest of the world resulted
in a general reduction in the prevalence
of typhoid fever. Infection is still highly
prevalent in resource-limited countries
and travelers. Reasons for this include the
lack of effective vaccine campaigns, avail-
ability of accurate diagnostic tests and the
emergence of antibiotic resistance, hin-
dered by the incomplete understanding
of bacterial pathogenesis and response to
infection by the native host.
To address this, in 2011 we re-
established controlled human infection
studies of S. Typhi in Oxford. A model
was developed using a sodium bicarbon-
ate buffer to neutralize gastric acid and
increase bacterial survival through the
stomach; neutralization of stomach acid
allows the use of lower challenge inocula
and a smoother pattern of clinical infec-
tion (Waddington et al., 2014b). Ingestion
with buffer resulted in a consistent pat-
tern of typhoid infection with an attack
rate of 65%, which developed after inges-
tion of 1–5×104 colony forming units.
Participants were managed after challenge
on an outpatient basis.
The development of this new chal-
lenge model will provide a standardized
approach to study typhoid infection that
will prove fundamental for the investi-
gation of immunobiology in the relevant
human host and the discovery, develop-
ment and evaluation of novel vaccines,
diagnostics and treatment modalities.
TYPHOID FEVER, A GLOBAL PROBLEM
Typhoid fever is an important health prob-
lem in resource-limited settings, while its
profile on the world stage is increasing
due to the risk of infection for travel-
ers (Leder et al., 2013). Approximately
80% of typhoid fever in Europe and
North America is associated with travel,
with the greatest proportion resulting
from travel to the Indian subcontinent
(Hendel-Paterson and Swanson, 2011).
Vaccination is recommended by the World
Health Organization (WHO) for all trav-
elers to countries where enteric fever is
endemic, regardless of the planned dura-
tion of stay in a typhoid-endemic setting.
Although licensed vaccines provide pro-
tection against S. Typhi and the live oral
vaccine Ty21a is thought to offer lim-
ited cross-protection against S. Paratyphi
B infection, there is currently no licensed
bivalent vaccine for S. Typhi and S.
Paratyphi A, the leading causes of enteric
fever (Pakkanen et al., 2012). Insights into
the dynamics of host-pathogen interac-
tions are crucial to understanding how S.
Typhi exploits host defenses during infec-
tion and is able to occupy its human-
restricted niche. Challenge studies could
be described as the ideal at-risk travel-
ers model, where naive adult participants
are given a bacterial inoculum sufficient
to cause typhoid fever. The model can
be used to assess the potential of pro-
phylactic vaccination to prevent infection
using typhoid challenge and to acceler-
ate the route to licensure, and field testing
potential of innovative diagnostics.
Increasing antimicrobial resistance
and the evolution of multi drug resis-
tant strains reduces treatment options in
many endemic settings (Dutta et al., 2014;
Walters et al., 2014). Chloramphenicol,
ampicillin and co-trimoxazole resis-
tance emerged throughout the Indian
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subcontinent and South East Asia dur-
ing the late 1980s (Holt et al., 2012).
The isolation of quinolone resistant S.
Typhi has become a cause for concern
as drug resistance patterns make treat-
ment options more difficult and costly.
Diagnostics at the point of care are impor-
tant for the prompt detection of causative
bacteria, early appropriate case manage-
ment and targeted antibiotic treatment
(Laxminarayan et al., 2013). Large, well
designed trials to determine optimal adult
and pediatric treatment policies to prevent
clinical relapse of enteric fever in endemic
areas are important for the management
of anti-microbial resistant S. Typhi and its
associated public health burden (Thaver
et al., 2009; Arjyal et al., 2011). In our own
challenge programme, there is an oppor-
tunity to use the model as a platform to
evaluate antibiotic treatment regimens
and inform on pharmacodynamics in the
resolution of infection.
Prevention of S. Typhi infection among
travelers through pre-travel vaccination
is fundamental as international travel
becomes more accessible and a signif-
icant cause of travel-associated illness
(Freedman et al., 2014). Government and
public health authorities are becoming
more involved in promoting immuniza-
tion, personal hygiene education as well as
implementing GeoSentinal sites to collect
surveillance data including patient demo-
graphic characteristics, detailed travel
history, vaccination status, and specific
typhoid fever disease diagnosis (Leder
et al., 2013). Practical applications for
human challenge models to characterize
infection rate, symptom severity, duration
of shedding and biomarkers of disease are
important for the identification of disease
and mechanisms of protective immunity.
Furthermore, the model may provide
important supportive data for licensure
of new travel vaccines for enteric fever.
WHY ARE HUMAN CHALLENGE
STUDIES SO UNIQUE ANDWHAT CAN
WE LEARN?
Most human Salmonella infections result
in gastroenteritis and are caused by
Salmonella Typhimurium or Salmonella
Enteritidis. S. Typhi, the predominant eti-
ologic agent of typhoid (enteric) fever, is
specifically adapted to only infect humans
with no known animal or environmental
reservoir. Animal models for invasive non-
typhoidal Salmonella (NTS) are avail-
able, an important source of human dis-
ease in the immunocompromised host
(Simon et al., 2011). Despite the discov-
ery and establishment of systemic (intra-
venous or intraperitoneal) and oral S.
Typhi murine infection models in human-
ized and knockout mice (Levine et al.,
2001; Andrews-Polymenis et al., 2010;
Song et al., 2010; Mathur et al., 2012),
the limited understanding of human infec-
tion has significantly hampered the devel-
opment of new vaccines. The availability
of tractable animal models of S. Typhi
infection is of significant scientific inter-
est but it must be argued that improved
understanding and assessment of S. Typhi
host-pathogen interactions can only effec-
tively be achieved through the study of its
natural host. The S. Typhi human chal-
lenge model is pivotal in addressing broad
themes of basic Salmonella infection.
Human challenge studies involve the
administration of S. Typhi to consenting
healthy adult volunteers with the intent to
deliberately induce infection under care-
fully controlled conditions. Such mod-
els are safe and provide a cost effective
method to expedite vaccine development
and facilitate the discovery and assess-
ment of novel diagnostics. In comparison
to large field trials designed to demon-
strate vaccine efficacy, challenge models
are more cost effective, less labor inten-
sive and can be completed within a shorter
study period. Typhoid challenge studies
using a relevant host can be extremely
informative and have historically con-
tributed to knowledge and understanding
of strain virulence, infectious dose, micro-
bial pathogenesis, immunity and the iden-
tification of potential vaccine candidates
(Hornick et al., 1970a,b, 2007). The re-
establishment in Oxford of a controlled
human infection model has provided a
rare opportunity to make direct com-
parisons to the findings from historical
human studies by using the same chal-
lenge strain (Quailes) (Waddington et al.,
2014b). The models provide clues to pos-
sible correlates of protection, and allow
direct comparisons between individuals
who do or do not succumb to infection.
The collection of baseline (pre-exposure)
samples for assessment in combination
with pre/post-vaccination and subsequent
challenge is a remarkable opportunity. The
ability to control the timing of infec-
tion in a well-defined study cohort is of
unique value and an important research
approach by which to understand dis-
ease pathogenesis, now greatly enhanced
by advances in scientific areas such as
functional genomics and systems biology
approaches. In addition, identification of
host genetic factors linked to infection sus-
ceptibility will supplement our knowledge
as genetic variation within distinct popu-
lations has been linked to defense against
typhoid fever (Ziakas et al., 2013).
Despite providing the opportunity for
study of S. Typhi infection in the natural
host, human challenge studies are associ-
ated with known limitations. Often only
a short-term duration of infection can be
studied due to early treatment and patient
safety, while the criteria for diagnosis of
typhoid fever in the model may differ from
that used in an endemic setting. Specific
details of the challenge model (includ-
ing the choice of microbial strain, method
of administration and the challenge dose)
may not extrapolate to the natural course
or mode of infection. Challenge volun-
teers may not represent the final target
population of the vaccine and observa-
tions may not always be transferable to
an endemic population due to inherent
differences in nutrition, host microbiome,
or the absence of co-infection with other
intestinal bacteria or parasites (Ahmer and
Gunn, 2011; Hallstrom and McCormick,
2011; Nuccio and Bäumler, 2014). As the
safety of consenting individuals is of the
upmost importance, the design of such
studies must be ethically sound, ensur-
ing minimal risk to participants while
maintaining scientific integrity (Miller and
Grady, 2001; Hope and McMillan, 2004).
DEVELOPMENT OF IMPROVED
DIAGNOSTICS
Diagnosis of enteric fever in an endemic
setting is still heavily reliant on clini-
cal presentation and notoriously unreli-
able tests reiterate the poor sensitivity and
specificity of current diagnostics (Parry
et al., 2011). The next generation diag-
nostic point of care test for S. Typhi
must be rapid, accurate and affordable in
the setting in which it is ultimately des-
tined, and ideally will not rely on expen-
sive equipment, nor highly skilled and
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trained clinical and laboratory person-
nel (Andrews et al., 2013). The search
for an improved gold standard typhoid
fever diagnostic remains a challenge for
all researchers, but one approach is to use
samples collected during challenge models
as an alternative to those from endemic-
settings (Baker et al., 2010; Nga et al.,
2010). The model provides a defined time
point at which infection takes place and
allows the collection of samples before,
during and after the onset of clinical dis-
ease. Longitudinal challenge model sam-
ples (including serum, plasma, saliva,
urine, stool and peripheral blood lympho-
cytes) collected in Oxford will be used to
support, validate or indeed refute the accu-
racy and suitability of a novel diagnostic
test.
Recent advances in Salmonella diag-
nostics include metabolomics for the
detection of Salmonella in blood dur-
ing infection. Relying on the identifica-
tion of a unique metabolomic signature
in an infected individual, this technique
has the potential to discriminate between
S. Typhi and S. Paratyphi A infection
(Näsström et al., 2014). Antibodymicroar-
rays are being used to identify potential
biomarkers of infection for application
in the development of novel diagnostic
tests and subunit vaccine targets (Liang
et al., 2013; Bhuiyan et al., 2014). These
approaches are being applied to the chal-
lenge model to validate their use at dif-
ferent stages of infection in a naive pop-
ulation. Simple antibody profiles in a
small blood sample collected upon hos-
pital presentation have been proposed as
an achievable typhoid/paratyphoid fever
diagnostic (TPTest) in an endemic setting
equipped with a basic microbiology labo-
ratory (Khanam et al., 2013). Using only
a few micro liters of a clinical specimen, it
is now possible to employ high through-
put screening techniques to identify early
signatures of the host response, thereby
increasing the possibility of a future diag-
nostic based on a non-invasive sample type
such as saliva or urine (Zaka-ur-Rab et al.,
2012; Das et al., 2013). Challenge stud-
ies provide a unique myriad of resources
which through discussion and develop-
ment with international collaborators has
the potential to improve both the quality
and standardization of future Salmonella
diagnostics.
CONCLUDING THOUGHTS
The knowledge gained from human chal-
lenge models will not only identify the
elusive correlate of protection, but will
inform and facilitate the accelerated devel-
opment of novel diagnostics, identifica-
tion of novel vaccine candidates, and
the targeted assessment of next gener-
ation bivalent or combination vaccines.
Human challenge models will continue to
be instrumental in unraveling the com-
plex pathways associated with infection
and will help address remaining questions
about S. Typhi pathogenesis. We acknowl-
edge the volunteers who participate in
Salmonella challenge trials and help in the
quest to conquer enteric fever.
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